APA (7th ed.) Citation

AT, P., J, M., K, K., E, B., K, S., AJ, R., . . . PL, S. (2026). MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: A phase I clinical trial. Nature communications, 17(1), . https://doi.org/10.1038/s41467-026-70653-3

Chicago Style (17th ed.) Citation

AT, Pearson, et al. "MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 Wild-type Salivary Gland Cancers: A Phase I Clinical Trial." Nature Communications 17, no. 1 (2026). https://doi.org/10.1038/s41467-026-70653-3.

MLA (9th ed.) Citation

AT, Pearson, et al. "MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 Wild-type Salivary Gland Cancers: A Phase I Clinical Trial." Nature Communications, vol. 17, no. 1, 2026, https://doi.org/10.1038/s41467-026-70653-3.